Gel safe and acceptable as approach to preventing HIV from anal sex

April 3, 2013

A reformulated version of an anti-HIV gel developed for vaginal use was found safe and acceptable by HIV-negative men and women who used it rectally, according to a Phase I clinical trial published today in PLOS ONE. The study, led by researchers with the U.S. National Institutes of Health (NIH)-funded Microbicide Trials Network (MTN), tested a reduced glycerin formulation of tenofovir gel, and has spurred the development of an expanded safety study of the gel, expected to launch later this year.

Rectal microbicides, -based antiretroviral products applied into the rectum with the use of an applicator, are being developed as an approach for preventing or reducing the of HIV from unprotected anal sex. Researchers are working on developing rectal-specific products as well as reformulations of vaginal products, specifically, gel.

The study, known as MTN-007, was the first to evaluate tenofovir gel reformulated with less , a common additive found in many gel-like products, in the hopes of making it better suited for use in the rectum. It began in October 2010 and enrolled 65 men and women at three sites – the University of Pittsburgh, University of Alabama at Birmingham and Fenway Health in Boston.

In MTN-007, study participants were randomly assigned to one of four study groups. Three of these groups were assigned to use one of the following products for a one-week period: a reduced glycerin formulation of tenofovir gel; a placebo gel containing no ; or a gel containing the spermicide nonoxynol-9. A fourth group did not use any gel but took part in all of the study-related procedures and tests, including physical and rectal exams.

Study results, preliminarily presented at a scientific meeting in 2012, indicated no significant differences in among the three gel groups. Eighty percent of participants reported minor side effects related to the use of study products, and 18 percent reported moderate side effects. (Two study participants reported severe adverse events, but they were not related to use of the study products.) Participants' adherence to the use of their assigned study products was high, with 94 percent using the products daily as directed. When asked about the likelihood that they would use the gel in the future, 87 percent of the participants who used the reformulated gel indicated they would likely use the gel again, compared to 93 percent of the placebo gel group, and 63 percent of the nonoxynol-9 gel group. In addition to assessing safety and acceptability, researchers also conducted gene expression testing, and noted changes in the activation of some genes in the reduced glycerin tenofovir gel group, which they will continue to assess in future rectal microbicide studies.

"We are very encouraged that the reformulated gel was quite safe, and that most people who used it said they would be willing to use it in the future," said Ian McGowan, M.D., Ph.D., co-principal investigator of the MTN and professor of medicine, Division of Gastroenterology, Hepatology and Nutrition and Department of Obstetrics, Gynecology and Reproductive Sciences, University of Pittsburgh School of Medicine. "These results have formed the basis for a follow-up study that should provide us with even more detailed information about the safety and acceptability of the gel."

Researchers are now in the final planning stages of a Phase II, multi-site trial of the reformulated gel called MTN-017 that will involve186 men who have sex with men and transgender women at clinical sites in Peru, South Africa, Thailand, and the U.S., including Puerto Rico. Participants will cycle through three study regimens: reformulated tenofovir gel used daily, reformulated tenofovir gel used before and after anal sex, and daily use of the antiretroviral tablet Truvada®. MTN-017 will allow researchers to collect additional information about the gel's safety and acceptability in the rectum, and compare it to the use of Truvada.

In addition to Dr. McGowan, other authors of the study include Craig Hoesley, M.D., University of Alabama; Ross Cranston, M.D., University of Pittsburgh; Philip Andrew, FHI 360; Laura Janocko, Ph.D., MTN and Magee-Womens Research Institute; James Dai, Fred Hutchinson Cancer Research Center; Alex Carballo-Dieguez, Ph.D., Columbia University; Ratiya Kunjara Na Ayudhya, BSMT, MTN; Jeanna Piper, M.D., Division of AIDS, National Institute of Allergy and Infectious Diseases; Florian Hladik, M.D., Ph.D., Fred Hutchinson Cancer Research Center; and Ken Mayer, M.D., Fenway Health.

MTN-007 was funded by the National Institute of Allergy and Infectious Diseases (NIAID) Division of AIDS (DAIDS) and the National Institute of Mental Health, both components of the NIH. Tenofovir gel was developed by Gilead Sciences, Inc., of Foster City, Calif., which assigned the rights for tenofovir gel to CONRAD, of Arlington, Va ., and the International Partnership for Microbicides of Silver Spring, Md., in December 2006.

CONRAD developed the reduced glycerin formulation of tenofovir gel evaluated in MTN-007 and it differs from the formulation originally developed for vaginal use. Although the vaginal gel produced a significant antiviral effect when used in the rectum, it was found to cause gastrointestinal side effects in some study participants in an earlier study called RMP-02/MTN-006.

The vaginal formulation of tenofovir gel continues to be evaluated for preventing the through vaginal sex in women. Ongoing is a Phase III trial called FACTS 001 that is testing its use before and after sex among women in South Africa. FACTS 001 hopes to replicate the results of CAPRISA 004, which found this regimen reduced the risk of HIV by 39 percent compared to placebo gel. The VOICE Study (Vaginal and Oral Interventions to Control the Epidemic), however, found daily use of the gel not effective among its ; most of the women did not use the product daily as recommended.

Explore further: Rectal formulation of tenofovir gel safe and acceptable in early phase clinical study

Related Stories

Rectal formulation of tenofovir gel safe and acceptable in early phase clinical study

March 6, 2012
A gel formulation of the antiretroviral drug tenofovir designed specifically for rectal use was found safe and acceptable, according to a Phase I clinical study led by the U.S. National Institutes of Health (NIH)-funded Microbicide ...

Reduced glycerin formulation of tenofovir vaginal gel safe for rectal use

May 17, 2012
A change in the formulation of tenofovir gel, an anti-HIV gel developed for vaginal use, may make it safer to use in the rectum, suggests a study published online this week in the Journal of Antimicrobial Chemotherapy. In ...

NIH discontinues tenofovir vaginal gel in 'VOICE' HIV prevention study

November 28, 2011
A large-scale clinical trial evaluating whether daily use of an antiretroviral-containing oral tablet or vaginal gel can prevent HIV infection in women is being modified because an interim review found that the gel, an investigational ...

Recommended for you

Scientists divulge latest in HIV prevention

July 25, 2017
A far cry from the 1990s "ABC" campaign promoting abstinence and monogamy as HIV protection, scientists reported on new approaches Tuesday allowing people to have all the safe sex they want.

Girl's HIV infection seems under control without AIDS drugs

July 24, 2017
A South African girl born with the AIDS virus has kept her infection suppressed for more than eight years after stopping anti-HIV medicines—more evidence that early treatment can occasionally cause a long remission that, ...

Meds by monthly injection might revolutionize HIV care (Update)

July 24, 2017
Getting a shot of medication to control HIV every month or two instead of having to take pills every day could transform the way the virus is kept at bay.

Candidate AIDS vaccine passes early test

July 24, 2017
The three-decade-old quest for an AIDS vaccine received a shot of hope Monday when developers announced that a prototype triggered the immune system in an early phase of human trials.

Paris spotlight on latest in AIDS science

July 21, 2017
Some 6,000 HIV experts gather in Paris from Sunday to report advances in AIDS science as fading hopes of finding a cure push research into new fields.

Scientists elicit broadly neutralizing antibodies to HIV in calves

July 20, 2017
Scientists supported by the National Institutes of Health have achieved a significant step forward, eliciting broadly neutralizing antibodies (bNAbs) to HIV by immunizing calves. The findings offer insights for HIV vaccine ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.